Xigen , a biopharmaceutical company, develops therapeutics to inhibit intracellular protein-protein interactions for the treatment of various diseases
Business Model:
Revenue: $0
Employees: 11-50
Address: Route de la
City: Epalinges
State: other
Zip: 1066
Country: CH
Xigen , a biopharmaceutical company, develops therapeutics to inhibit intracellular protein-protein interactions for the treatment of various diseases
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2005 | Series A | 3 | $21M |
Initiative Capital Tilocor Life Science VI Partners Initiative Capital Tilocor Life Science VI Partners |
11/2009 | Series B | 1 | $20M |
Tilocor Life Science Tilocor Life Science |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|